Our mission is to provide patients and our partners with value-added medicines. Our biodegradable sustained-release drug delivery systems help improve medication adherence and allow for cost-effective therapies.
Based on our technology platform, we build on a growing own and partnered development pipeline.
We hereby cover the entire value chain, from (co-)development to manufacturing and commercialization or out-licensing. Based on our unparalleled expertise in formulation development, we support global as well as local pharma and biotech partners in developing and manufacturing high-quality products and life-cycle solutions.
We have two approved products, goserelin and leuprorelin implants, which are distributed worldwide through both local and global pharma partners.
Philipp Karbach has been with AMW since 2016, since June 2023 as Chief Executive Officer and prior to that, among other, as Chief Operating Officer and Chief Financial Officer of the Company. Mr. Karbach has more than 20 years of experience in the healthcare sector in marketing, business operations and strategy as well as finance. Prior to AMW, he held various positions at i-SOLUTIONS Health, iSOFT/CSC, ICW and Siemens Healthcare. He holds a diploma in Health Economics from the University of Bayreuth, Germany.
As Chief Operating Officer (COO), Sebastian Herzog heads the Operations division, covering Manufacturing, Supply Chain and Logistics, since April 2023. As an experienced executive with global expertise in the chemical-pharmaceutical and consumer health industries, he has shaped transformation processes in various companies, including the Ontex Group, Gruenenthal GmbH and Bayer AG. Throughout his career, he gained significant experience in the areas of lean manufacturing, supply chain, project engineering and quality. Mr. Herzog holds a Master of Business Administration in Production Management from Koblenz University of Applied Sciences as well as education and training degrees in engineering and chemical process engineering.
Dr. Serafimov is an experienced business leader with a track record of profitable growth in originator specialty drugs, generics and B2B business. With more than 15 years of professional experience in the pharmaceutical industry and management consulting, he combines a strong strategic business planning mindset with a profound commercial operations background. In global and local roles, he has gained extensive experience across the full product lifecycle, from multiple product launches to effective lifecycle management of mature brands. Dr. Serafimov joins AMW from Centrient Pharmaceuticals, The Hague, NL, a Bain Capital Portfolio Company, where he headed the Global Business Excellence team. He started his industry career in a consulting role at IMS Consulting (today IQVIA), before he moved to various global and local leadership positions at Novo Nordisk, Zurich and Mainz, and Sandoz International GmbH, Munich. Dr. Serafimov holds biochemistry and chemistry degrees from the universities of Heidelberg, Oxford, as well as from ETH Zurich.
Carolin Unger heads the Human Resources department as Chief People Officer since January 2022. In addition, she has taken over the General Affairs department since April 2023. In her 15 years’ experience in leading positions, she was responsible for implementing HR strategies as well as establishing and managing all relevant HR services in an international environment. Ms. Unger holds a diploma from Munich University of Applied Sciences, Germany.
Matthias Dittmer, Vice President Finance and IT, assumed responsibility for this area in October 2023. In his previous leadership positions, including at Eurofins Scientific, TE Connectivity and Sirona Dental Systems, he gained extensive experience in controlling and financial group reporting as well as implementing ERP systems in complex, highly regulated industries with international structures. Mr. Dittmer holds a degree in economics from Ludwig-Maximilians-University in Munich, Germany.
Dr. Andrey Molchanov heads the Regulatory Affairs department as Vice President since April 2021. In addition, he took over the Business Development department in October 2022. Due to his previous experience in leading positions, he has extensive expertise in the area of pharmaceutical issues relevant to marketing authorisation. Dr. Molchanov studied pharmacy, holds a PhD from the Free University of Berlin and an Executive Master in Marketing and Sales from ESADE/SDA Bocconi, the top 10 business schools in the EU.
Dr. Martina Wilhelm heads the Quality department as Vice President since July 2022. She is responsible for the overall management of quality control and quality assurance at AMW. She has been working within the GMP-regulated environment for more than 20 years, from setting-up to complete steering of quality teams and structures. In the course of her career, Dr. Wilhelm has held the position of Qualified Person in various pharmaceutical companies. She studied Chemistry and holds a PhD from Technical University of Munich, Germany.
Dr. Eric Wittchow leads the department as Vice President R&D since May 2022. He has more than 20 years of international experience in the development of combination products at medium-sized and large medical technology and pharmaceutical companies. His innovative ideas in the field of degradable materials and local drug delivery led to several approvals, patents and publications. Dr. Wittchow studied Chemistry and a minor in polymer chemistry and pharmacology at Universities in Erlangen-Nuremberg, Heidelberg, Marburg and Bonn.
Scientific Advisory Board
Since 2015, Prof. Merkel has been a professor of Drug Delivery in the Department of Pharmacy at Ludwig-Maximilians-Universität (LMU) Munich, Germany. As an internationally renowned expert in novel and targeted drug delivery systems, including RNA delivery systems, she is advising AMW on scientific and strategic topics.
Dr Dirk Schrader is an expert in all areas of technical operations and supply chain management in the pharmaceutical industry. He has been responsible for Technical Operations at Bayer Pharma, Bristol-Myers Squibb and AstraZeneca, among others, and brings a lot of experience from the Asian market and leadership skills. With his experience and pharmaceutical knowledge, he supports AMW in technical matters. Additionally, he holds the Financial Times Non-Executive Director Diploma.
Dr. Georg Ingram is an expert in business development, licensing and project management. With more than 20 years of experience in various companies, such as Pharmascience Inc, Actavis and Alvogen, he enriches AMW with diverse background knowledge.
Achieved a key milestone in opening new markets with the final report of the first Notified Body Opinion (NBO). Conclusion of further licensing and manufacturing agreements for the implants goserelin and leuprorelin
Expanding the partnership with Zentiva; strategic focus on biodegradable implants and transfer of the buprenorphine and rivastigmine transdermal systems to Adhex Pharma; Goserelin approved in 29 countries, leuprorelin approved in 8 countries
Market approval for the leuprorelin implant and start of sales under the trade name Leugon®; conclusion of further licensing and manufacturing agreements for the goserelin and leuprorelin implants; completion of the new research and development center in Warngau; goserelin with market approval in 22 countries
Sales launch of the goserelin implant and the buprenorphine and rivastigmine transdermal systems
2013 – 2015
Market approval for the goserelin implant as well as for buprenorphine and rivastigmine transdermal systems and conclusion of initial licensing and manufacturing agreements with global pharmaceutical partners
2009 – 2012
AMW obtains manufacturing authorization for medical devices and sets up production facilities; Start of clinical trials for implants
Foundation of AMW GmbH